Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3350558
Max Phase: Preclinical
Molecular Formula: C28H23Cl2N3O7
Molecular Weight: 584.41
Molecule Type: Small molecule
Associated Items:
ID: ALA3350558
Max Phase: Preclinical
Molecular Formula: C28H23Cl2N3O7
Molecular Weight: 584.41
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CO[C@H]1[C@H](O)[C@@H](O)[C@H](n2c3c(Cl)cccc3c3c4c(c5c6cccc(Cl)c6[nH]c5c32)C(=O)N(C)C4=O)O[C@@H]1CO
Standard InChI: InChI=1S/C28H23Cl2N3O7/c1-32-26(37)17-15-10-5-3-7-12(29)19(10)31-20(15)22-16(18(17)27(32)38)11-6-4-8-13(30)21(11)33(22)28-24(36)23(35)25(39-2)14(9-34)40-28/h3-8,14,23-25,28,31,34-36H,9H2,1-2H3/t14-,23-,24-,25-,28-/m1/s1
Standard InChI Key: IDJBSIHZPGRCAI-BJIUMZSASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 584.41 | Molecular Weight (Monoisotopic): 583.0913 | AlogP: 3.59 | #Rotatable Bonds: 3 |
Polar Surface Area: 137.25 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 4 |
#RO5 Violations: 1 | HBA (Lipinski): 10 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 11.86 | CX Basic pKa: | CX LogP: 2.81 | CX LogD: 2.81 |
Aromatic Rings: 5 | Heavy Atoms: 40 | QED Weighted: 0.24 | Np Likeness Score: 0.68 |
1. Moreau P, Anizon F, Sancelme M, Prudhomme M, Bailly C, Carrasco C, Ollier M, Sevère D, Riou JF, Fabbro D, Meyer T, Aubertin AM.. (1998) Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle., 41 (10): [PMID:9572888] [10.1021/jm970843+] |
2. Moreau P, Anizon F, Sancelme M, Prudhomme M, Bailly C, Carrasco C, Ollier M, Sevère D, Riou JF, Fabbro D, Meyer T, Aubertin AM.. (1998) Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle., 41 (10): [PMID:9572888] [10.1021/jm970843+] |
3. Moreau P, Anizon F, Sancelme M, Prudhomme M, Sevère D, Riou JF, Goossens JF, Hénichart JP, Bailly C, Labourier E, Tazzi J, Fabbro D, Meyer T, Aubertin AM.. (1999) Synthesis, mode of action, and biological activities of rebeccamycin bromo derivatives., 42 (10): [PMID:10346933] [10.1021/jm980702n] |
4. Anizon F, Belin L, Moreau P, Sancelme M, Voldoire A, Prudhomme M, Ollier M, Sevère D, Riou JF, Bailly C, Fabbro D, Meyer T.. (1997) Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group., 40 (21): [PMID:9341921] [10.1021/jm9702084] |
Source(1):